As of Friday close, Esperion Therapeutics Inc.’s (NASDAQ:ESPR) stock was down -$0.1, moving down -9.16 percent to $0.99. The average number of shares traded per day over the past five days has been 8,237,540 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.4298 fall in that time frame. In the last twenty days, the average volume was 5,103,655, while in the previous 50 days, it was 3,713,240.
Since last month, ESPR stock retreated -28.76%. Shares of the company fell to $0.8500 on 09/22/23, the lowest level in the past month. A 52-week high of $8.87 was reached on 01/10/23 after having rallying from a 52-week low of $1.02. Since the beginning of this year, ESPR’s stock price has dropped by -84.11% or -$5.2398, and marked a new high 4 times. However, the stock has declined by -88.84% since its 52-week high.
ESPR stock investors should be aware that Esperion Therapeutics Inc. (ESPR) stock had its last reported insider trading activity 3 days ago on Sep 20. Warren Eric, the Chief Commercial Officer of the company, disposed of 742 shares for $1.25 on Sep 20. It resulted in a $924 divestment by the insider. Warren Eric sold 243 shares at an average price of $1.41 on Aug 18. The insider now owns 69,060 shares following the transaction. On Jul 19, Chief Commercial Officer Warren Eric sold 106 shares at $1.58 apiece. The transaction was valued at $168.
Financial Health
In the three months ended June 29, Esperion Therapeutics Inc.’s quick ratio stood at 1.70, while its current ratio was 2.20, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 66.90% percent. Based on annual data, ESPR earned $48.51 million in gross profit and brought in $75.47 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 280.90%. Return on equity (ROE) for the past 12 months was 67.40%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. ESPR’s revenue rose 26.95% to $24.33 million during the quarter, while net income inched up to $25.79 million. While analysts expected Esperion Therapeutics Inc. to report -$0.61 quarterly earnings, the actual figure was -$0.46 per share, beating the consensus estimate by 24.60%. During the quarter, the company generated -$36.66 million in EBITDA. The liabilities of Esperion Therapeutics Inc. were 606.6 million at the end of its most recent quarter ended June 29, and its total debt was $522.9 million. The value of shareholders’ equity is $106.99 million.
Technical Picture
This quick technical analysis looks at Esperion Therapeutics Inc.’s (ESPR) price momentum. With a historical volatility rate of 62.21%, the RSI 9-day stood at 20.08% on 22 September.
With respect to its five-day moving average, the current Esperion Therapeutics Inc. price is down by -30.27% percent or -$0.4298. At present, ESPR shares trade -29.77% below its 20-day simple moving average and -30.27% percent below its 100-day simple moving average. However, the stock is currently trading approximately -34.42% below its SMA50 and -86.78% below its SMA200.
Stochastic coefficient K was 9.70% and Stochastic coefficient D was 7.78%, while ATR was 0.1532. Given the Stochastic reading of 17.97% for the 14-day period, the RSI (14) reading has been calculated as 26.70%. As of today, the MACD Oscillator reading stands at -0.1666, while the 14-day reading stands at -0.2240.
Analyst Ratings
Northland Capital upgraded its rating on Esperion Therapeutics Inc. (NASDAQ: ESPR) to a Market perform in a note to investors on August 01, 2023. The analysts firm previously had an Under perform rating on the stock.Esperion Therapeutics Inc. (ESPR) has been rated Buy by analysts. According to 0 brokerage firms, ESPR is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Esperion Therapeutics Inc. stock as buy, with 7 recommending it as overweight.
With a median target price of $9.50, the current consensus forecast for the stock is $2.00 – $22.00. Based on these forecasts, analysts predict Esperion Therapeutics Inc. (ESPR) will achieve an average price target of $11.13.
